eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | leukemia, acute myeloid |
| Comorbidity | C0026946|fungal infection |
| Sentences | 6 |
| PubMedID- 23042005 | Mucormycosis is an increasingly recognized invasive fungal infection (ifi) in patients with acute myeloid leukemia (aml) and after allogeneic (allo) stem cell transplantation (hsct); it is mainly due to the severe and prolonged neutropenia related to high-dose chemotherapy. |
| PubMedID- 24075616 | Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. |
| PubMedID- 20237074 | Background: voriconazole and posaconazole are used prophylactically against invasive fungal infection (ifi) in patients with acute myeloid leukaemia (aml). |
| PubMedID- 20463605 | Successful nonmyeloablative allogeneic stem cell transplantation for therapy-related acute myelogenous leukemia in a patient with preexisting visceral fungal infection. |
| PubMedID- 25049247 | Posaconazole tablets, a new oral formulation of posaconazole, can be effective when given as antifungal prophylaxis to neutropenic patients at high risk for invasive fungal infection (e.g., those with acute myelogenous leukemia or myelodysplastic syndrome). |
| PubMedID- 26188835 | Purpose: posaconazole is effective for the prophylaxis of invasive fungal infections (ifis) in patients with acute myeloid leukemia or myelodysplastic syndrome during remission induction chemotherapy. |
Page: 1